Lenalidomide and Low Dose Dexamethasone Induction Therapy Followed by Low Dose Melphalan, Prednisone, Lenalidomide and Bortezomib Sequential Maintenance Therapy for Newly Diagnosed High-Risk Multiple Myeloma.

Trial Profile

Lenalidomide and Low Dose Dexamethasone Induction Therapy Followed by Low Dose Melphalan, Prednisone, Lenalidomide and Bortezomib Sequential Maintenance Therapy for Newly Diagnosed High-Risk Multiple Myeloma.

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Dec 2016

At a glance

  • Drugs Lenalidomide (Primary) ; Bortezomib; Dexamethasone; Melphalan; Prednisone
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Aug 2014 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 09 Apr 2014 Planned End Date changed from 1 May 2018 to 1 May 2014, as per ClinicalTrials.gov record.
    • 19 Sep 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top